Duloxetine versus venlafaxine in the treatment of unipolar and bipolar depression

Clinica Terapeutica

Volumn 161, Issue 4, 2010, Pages 321-327

  Serafini, Gianluca ^a   Pompili, M ^a,b   Del Casale, A ^a   Mancini, M ^c   Innamorati, M ^d   Lester, D ^e   Girardi, P ^a   Tatarelli, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MCLEAN HOSPITAL   (United States)

^c Eli Lilly Medical Center   (Italy)

^d UNIVERSITÀ EUROPEA DI ROMA   (Italy)

^e RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

Author keywords

Bipolar depression; Efficacy; Safety; SNRIs; Unipolar depression

Indexed keywords

DULOXETINE; LITHIUM; OLANZAPINE; QUETIAPINE; VALPROIC ACID; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; QUALITY OF LIFE; REMISSION; SHORT FORM 36; SUICIDAL IDEATION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 77957295925     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bymaster FP, Dreshfield-Ahmad LJ, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharm 2001; 25:871-80
2. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitorduloxetine: a review of its preclinical pharmacolo-gy, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11:1475-93
3. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psych 2000; 57:503-9
4. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002; 58:169-222
5. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psych 2002; 52:1166-74 (Pubitemid 35477672)
6. Smith GR, Kramer TL, Hollenberg JA, et al. Validity of the Depression-Arkansas (D-ARK) Scale: a tool for measuring major depressive disorder. Ment Health Serv Res 2002; 4:167-73
7. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978-86
8. Thase ME, Denko T. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol 2008; 4:53-91
9. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psych 2004; 65:1190-6
10. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psych 2005; 66:1312-20
11. Papakostas GI, Petersen T, Sklarsky KG, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psych Res 2007; 149:195-200 (Pubitemid 46108106)
12. Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharm 2008;23:181-7
13. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 28; 373(9665):746-58
14. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psych Res 2008; 42:22-34
15. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2008; 39(12):1-10
16. Allgulander C, Nutt D, Detke M, et al. A noninferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharm 2008; 22:417-25
17. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008; 25(7):E1-11
18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-96
19. Hamilton M. A Rating Scale for depression. J Neurol Neurosurg Psych 1960; 23:56-62
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-5
21. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20:22-33: quiz 34-57 (Pubitemid 29001829)
23. Rush AJ, Thase ME. Strategies and tactics in the treatment of chronic depression. J Clin Psych 1997; 58 Suppl 13:23-9
24. Thase ME, Macfadden W, Weisler RH, et al. BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharm 2006; 26(6):600-9. Erratum in: J Clin Psychopharm 2007; 27(1):51
25. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J. Royal Statistical Society, Series B 1995; 57:289-300
26. Malhi GS, Adams D, Lampe L, et al. Northern Sydney Central Coast Mental Health Drug & Alcohol; NSW Health Clinical Redesign Program; CADE Clinic, University of Sydney. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009; (439):27-46
27. Dunner DL, D'Souza DN, Kajdasz DK, et al. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005; 87:115-9